Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
Yet another publication showing #HIVEC to be a viable, safe and well tolerated treatment for BCG failure patients with both #mitomycin and #epirubicin.
Thanks to @francescok86 for his great work.
#BladderCancer #Hyperthermia #BCG
https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/125687-outcomes-and-complications-of-hyperthermic-intravesical-chemotherapy-using-mitomycin-c-or-epirubicin-for-patients-with-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-treatment-failure.html
📢NEXT WEEK📢Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 NOV-18.30 CEST
🗣Dr @AndreasBrandl8, Dr @alarjosan, Dr Diane Goéré & Dr Pieter Tanis ➡️https://lnkd.in/gNsACYN
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer @CombatCancer
They don’t do an emoji for HIPEC with agitation bubbles of CO2.
Is this close enough @alarjosan?
🛁🛁🛁🛁🛁
Laparoscopic cytoreductive surgery and HIPEC for a limited low-grade pseudomyxoma peritonei.
Performed by Dr @alarjosan and team at @HUReinaSofia
👏🏻👏🏻👏🏻👏🏻
📢Webinar Alert📢
Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 November-18.30 CEST
🗣Dr @AndreasBrandl8, Dr Alvaro-Arjona-Sanchez, Dr Diane Goéré & Dr Pieter Tanis
👉https://www.essoweb.org/courses/
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer
Three of our portfolio companies (@CombatCancer @LightpointMed
and @entiahealth) named by Coutts as "#medtech marvels supporting the NHS"
Coutts backs med-tech marvels supporting NHS
Meet four of the firms forging the future of health care with help from our clients
www.coutts.com
To register for this Friday's webinar (5-6 UK) click on the Eventbrite link
#HIVEC #BCGUnresponsive
HIVEC for BCG Unresponsive
Find out more about HIVEC in BCG Unresponsive Patients with Clinical Discussion and Live Q&A. EAU20 Presented Data.
www.eventbrite.co.uk
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
@cordekroon @HUReinaSofia @ESSOnews @operarelcancer @SWexner @DeliaCortesGuir @FarazKh65499316 @dr_mohammadyami @AndreasBrandl8 @annafagottimd Closed system with CO2 agitation system @CombatCancer @jansenaxel is an option for drug distribution
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.
Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD
There are some great posters @ #BLADDR18 #HIVEC pic.twitter.com/bDnahheB4s
— Combat Medical #HIVEC #HIPEC (@CombatCancer) September 20, 2018
